CN103349671A - Resveratrol and spirulina composition and preparations and preparation method thereof - Google Patents
Resveratrol and spirulina composition and preparations and preparation method thereof Download PDFInfo
- Publication number
- CN103349671A CN103349671A CN2013103360324A CN201310336032A CN103349671A CN 103349671 A CN103349671 A CN 103349671A CN 2013103360324 A CN2013103360324 A CN 2013103360324A CN 201310336032 A CN201310336032 A CN 201310336032A CN 103349671 A CN103349671 A CN 103349671A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- purity
- adds
- ethanol
- backflow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 121
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 121
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 121
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 121
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 238000002360 preparation method Methods 0.000 title claims abstract description 87
- 235000016425 Arthrospira platensis Nutrition 0.000 title claims abstract description 36
- 240000002900 Arthrospira platensis Species 0.000 title claims abstract description 36
- 229940082787 spirulina Drugs 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 77
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 54
- 239000008103 glucose Substances 0.000 claims abstract description 54
- 239000007787 solid Substances 0.000 claims abstract description 36
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 34
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 32
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 32
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 17
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 17
- 239000011718 vitamin C Substances 0.000 claims abstract description 17
- 239000002671 adjuvant Substances 0.000 claims abstract description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 6
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 6
- 229960004853 betadex Drugs 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 178
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 229960004756 ethanol Drugs 0.000 claims description 54
- 239000009636 Huang Qi Substances 0.000 claims description 32
- 210000000582 semen Anatomy 0.000 claims description 30
- 235000009392 Vitis Nutrition 0.000 claims description 27
- 241000219095 Vitis Species 0.000 claims description 27
- 239000002893 slag Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 21
- 241001061264 Astragalus Species 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 235000006533 astragalus Nutrition 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 18
- 210000004233 talus Anatomy 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 12
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 11
- 229930195725 Mannitol Natural products 0.000 claims description 11
- 239000000594 mannitol Substances 0.000 claims description 11
- 235000010355 mannitol Nutrition 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 229920000881 Modified starch Polymers 0.000 claims description 10
- 238000006555 catalytic reaction Methods 0.000 claims description 10
- GDHNBPHYVRHYCC-SNAWJCMRSA-N 1,3-dimethoxy-5-[(e)-2-(4-methoxyphenyl)ethenyl]benzene Chemical compound C1=CC(OC)=CC=C1\C=C\C1=CC(OC)=CC(OC)=C1 GDHNBPHYVRHYCC-SNAWJCMRSA-N 0.000 claims description 9
- -1 3,5-dimethoxy-benzyl Chemical group 0.000 claims description 9
- 229920003091 Methocel™ Polymers 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims description 9
- 239000007962 solid dispersion Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000004132 cross linking Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- VFZRZRDOXPRTSC-UHFFFAOYSA-N 3,5-Dimethoxybenzaldehyde Chemical compound COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 230000001335 demethylating effect Effects 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HYXJXCNHNYUWAZ-UHFFFAOYSA-N 2-methoxy-2-phenylacetonitrile Chemical compound COC(C#N)C1=CC=CC=C1 HYXJXCNHNYUWAZ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 claims description 3
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 claims description 3
- 229960000540 polacrilin potassium Drugs 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 claims description 3
- CRUISIDZTHMGJT-UHFFFAOYSA-L zinc;dichloride;hydrochloride Chemical compound Cl.[Cl-].[Cl-].[Zn+2] CRUISIDZTHMGJT-UHFFFAOYSA-L 0.000 claims description 3
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 238000003684 Perkin reaction Methods 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 238000006114 decarboxylation reaction Methods 0.000 claims description 2
- 230000017858 demethylation Effects 0.000 claims description 2
- 238000010520 demethylation reaction Methods 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 238000006317 isomerization reaction Methods 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 56
- 210000004369 blood Anatomy 0.000 abstract description 55
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 abstract 1
- 229940047169 astragalus root extract Drugs 0.000 abstract 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 abstract 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 201000001421 hyperglycemia Diseases 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 16
- 238000003304 gavage Methods 0.000 description 16
- 230000037396 body weight Effects 0.000 description 14
- 150000001720 carbohydrates Chemical class 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 229960003105 metformin Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010007191 Capillary fragility Diseases 0.000 description 2
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- CCAWDIFJOBKBSE-UHFFFAOYSA-N 1-(chloromethyl)-3,5-dimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1 CCAWDIFJOBKBSE-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Compositions | Consumption (g) |
Spirulina | 40 |
High-purity resveratrol | 17 |
The composition of compositions | Consumption (g) |
Spirulina | 10 |
High- |
5 |
Radix Astragali extract | 1 |
Tartary buckwheat extract | 1 |
Vitamin C | 0.5 |
The composition of solid preparation | Consumption (g) |
Spirulina | 100 |
High-purity resveratrol | 30 |
Radix Astragali |
15 |
|
15 |
Vitamin C | 3 |
|
20 |
|
5 |
Low-substituted hydroxypropyl cellulose | 12 |
|
5 |
|
5 |
Hydrogenated |
5 |
The composition of solid preparation | Consumption (g) |
Spirulina | 35 |
High-purity resveratrol | 13 |
Radix Astragali extract | 2.5 |
Tartary buckwheat extract | 2.5 |
Vitamin C | 0.75 |
Xylitol | 8 |
Dextrin | 2 |
Polyvinylpolypyrrolidone | 4 |
Hypromellose | 3 |
Macrogol 4000 | 3 |
The composition of solid preparation | Consumption (g) |
Spirulina | 50 |
High-purity resveratrol | 10 |
Radix Astragali extract | 10 |
Tartary buckwheat extract | 10 |
Vitamin C | 2 |
HP-β- |
5 |
Hydroxy methocel | 10 |
Microcrystalline Cellulose | 10 |
Silicon dioxide | 2.5 |
Magnesium stearate | 0.5 |
The composition of solid preparation | Consumption (g) |
Spirulina | 60 |
High- |
15 |
|
5 |
|
5 |
Vitamin C | 1 |
The glucose group-beta-cyclodextrin | 10 |
|
5 |
|
5 |
Silicon dioxide | 1 |
Magnesium stearate | 1 |
The composition of solid preparation | Consumption (g) |
Spirulina | 55 |
High-purity resveratrol | 12 |
Radix Astragali extract | 7.5 |
Tartary buckwheat extract | 7.5 |
Vitamin C | 1.5 |
The glucose group-beta- |
5 |
Ethyl-beta-schardinger dextrin- | 2 |
Pregelatinized Starch | 10 |
Polacrilin potassium | 10 |
Polyethylene glycol 6000 | 5 |
Micropowder silica gel | 0.8 |
The composition of solid preparation | Consumption (g) |
Spirulina | 80 |
High- |
25 |
Radix Astragali extract | 12.5 |
Tartary buckwheat extract | 12.5 |
Vitamin C | 2.5 |
HP-β- |
20 |
Lactose | 10 |
Polyvidone | 10 |
|
5 |
Hydroxyethylmethyl- |
5 |
The composition of solid preparation | Consumption (g) |
Spirulina | 70 |
High- |
20 |
Radix Astragali extract | 12 |
Tartary buckwheat extract | 12 |
Vitamin C | 1.5 |
|
20 |
|
15 |
Cross-linking sodium carboxymethyl cellulose | 8 |
Index | Before the treatment (mmol/L) | After the treatment (mmol/L) |
Insulin | 9.52±3.81 | 13.26±3.46 |
Fasting glucose | 10.12±4.17 | 6.48±3.19 |
The red albumin of saccharifying | 14.3±4.20 | 10.29±3.84 |
Glyceric acid fat | 3.30±1.80 | 2.61±0.85 |
Cholesterol | 8.12±2.45 | 6.43±2.05 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310336032.4A CN103349671B (en) | 2013-08-02 | 2013-08-02 | A kind of resveratrol Spirulin composition and preparation thereof and method for making |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310336032.4A CN103349671B (en) | 2013-08-02 | 2013-08-02 | A kind of resveratrol Spirulin composition and preparation thereof and method for making |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103349671A true CN103349671A (en) | 2013-10-16 |
CN103349671B CN103349671B (en) | 2015-08-12 |
Family
ID=49306150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310336032.4A Active CN103349671B (en) | 2013-08-02 | 2013-08-02 | A kind of resveratrol Spirulin composition and preparation thereof and method for making |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103349671B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104522679A (en) * | 2014-12-03 | 2015-04-22 | 安徽哈博药业有限公司 | A vitamin c chewable tablet |
EP2944202A1 (en) * | 2014-05-14 | 2015-11-18 | Lypo C AB | A method for manufacturing a mixture of lypo-spheric vitamin C and a mixture of lypo-spheric vitamin C |
CN109620857A (en) * | 2019-01-16 | 2019-04-16 | 浙江大学 | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine |
CN110133078A (en) * | 2019-04-25 | 2019-08-16 | 广州万孚生物技术股份有限公司 | Glutamic-pyruvic transaminase Electrochemical Detection composition, its application, electrochemical sensor and detection method |
WO2024040630A1 (en) * | 2022-08-23 | 2024-02-29 | 南京盛德生物科技研究院有限公司 | Composition for controlling blood glucose, preparation method therefor, and use of same in reducing gi value of foods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836689A (en) * | 2005-12-02 | 2006-09-27 | 甘肃凯源生物技术开发中心 | Tablet containing F.tataricum and spirulina spp. , and its preparation method |
CN101396517A (en) * | 2007-09-29 | 2009-04-01 | 马万里 | Chinese medicine composition for treating diabetes |
-
2013
- 2013-08-02 CN CN201310336032.4A patent/CN103349671B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1836689A (en) * | 2005-12-02 | 2006-09-27 | 甘肃凯源生物技术开发中心 | Tablet containing F.tataricum and spirulina spp. , and its preparation method |
CN101396517A (en) * | 2007-09-29 | 2009-04-01 | 马万里 | Chinese medicine composition for treating diabetes |
Non-Patent Citations (2)
Title |
---|
刘佳等: "白藜芦醇治疗2型糖尿病及其相关疾病作用的分子机制研究进展", 《南京中医药大学学报》, no. 02, 31 December 2010 (2010-12-31), pages 158 - 160 * |
刘建林等: "番石榴的综合利用现状及发展前景", 《中国林副特产》, no. 6, 31 December 2005 (2005-12-31), pages 60 - 62 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2944202A1 (en) * | 2014-05-14 | 2015-11-18 | Lypo C AB | A method for manufacturing a mixture of lypo-spheric vitamin C and a mixture of lypo-spheric vitamin C |
CN104522679A (en) * | 2014-12-03 | 2015-04-22 | 安徽哈博药业有限公司 | A vitamin c chewable tablet |
CN109620857A (en) * | 2019-01-16 | 2019-04-16 | 浙江大学 | Peanut coat active component and its preparing the application in anti-fat antidiabetic medicine |
CN109620857B (en) * | 2019-01-16 | 2021-05-25 | 浙江大学 | Peanut coat active component and application thereof in preparation of anti-obesity and anti-diabetic drugs |
CN110133078A (en) * | 2019-04-25 | 2019-08-16 | 广州万孚生物技术股份有限公司 | Glutamic-pyruvic transaminase Electrochemical Detection composition, its application, electrochemical sensor and detection method |
WO2024040630A1 (en) * | 2022-08-23 | 2024-02-29 | 南京盛德生物科技研究院有限公司 | Composition for controlling blood glucose, preparation method therefor, and use of same in reducing gi value of foods |
Also Published As
Publication number | Publication date |
---|---|
CN103349671B (en) | 2015-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2520305B1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
CN102274244B (en) | Cassia bark polyphenol extract and preparation method and application thereof | |
CN101559092B (en) | Application of eucommia ulmoides extracts | |
CN100455291C (en) | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases | |
CN101361795B (en) | Medicine composition for treating cerebrovascular disease and preparation method thereof | |
CN103349671B (en) | A kind of resveratrol Spirulin composition and preparation thereof and method for making | |
CN1923241B (en) | Medicine composition containing epimedium extract, uncaria extract, and gastrodine, and its preparation and use | |
IL192791A (en) | Extract of xanthoceras sorbifolia bunge and extraction and uses thereof | |
CN103585192A (en) | Preparation method and application of Aleuritopteris argentea Fee extract | |
CN100486606C (en) | Total sennoside extract for treating constipation and its extraction process | |
CN1931233B (en) | Medicine composition of red sage and epimedium for treating cardiac and cerebral vascular diseases | |
CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
CN108524811A (en) | Reduce uric acid, cholesterol, three high Chinese medicine compositions and its preparation method for the treatment of | |
CN101591374A (en) | A kind of steroidal compounds, its preparation method and contain their pharmaceutical composition and purposes | |
CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
CN103432420A (en) | Traditional Chinese medicine composition for treating diabetes, and preparation method and detection method thereof | |
CN101019897A (en) | Antitumor medicine composition and its prepn | |
CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
CN100563647C (en) | The Pharmaceutical composition of Herba Erigerontis and sodium tanshinon IIA silate injection | |
CN109303785B (en) | Application of lobetyolin analog compound in preparation of medicine for treating arrhythmia | |
CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same | |
CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
CN103263581A (en) | Shuangshen capsule for reducing blood sugar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 734000 No. 87 North Ring Road, Ganzhou District, Zhangye, Gansu. Patentee after: Gansu Kaiyuan Biotechnology Development Center Co.,Ltd. Country or region after: China Patentee after: Luo Guanghong Patentee after: Zu Tingxun Patentee after: Yang Shenghui Patentee after: Wang Danxia Address before: 734000 No. 87 North Ring Road, Ganzhou District, Zhangye, Gansu. Patentee before: GANSU KAIYUAN BIOTECHNOLOGY DEVELOPMENT CENTER Country or region before: China Patentee before: Luo Guanghong Patentee before: Zu Tingxun Patentee before: Yang Shenghui Patentee before: Wang Danxia |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240314 Address after: 734000 in Hexi college, No. 846, Beihuan Road, Ganzhou District, Zhangye City, Gansu Province Patentee after: Gansu Kaiyuan Biotechnology Development Center Co.,Ltd. Country or region after: China Address before: 734000 No. 87 North Ring Road, Ganzhou District, Zhangye, Gansu. Patentee before: Gansu Kaiyuan Biotechnology Development Center Co.,Ltd. Country or region before: China Patentee before: Luo Guanghong Patentee before: Zu Tingxun Patentee before: Yang Shenghui Patentee before: Wang Danxia |